Beyond GLP-1: The Next Horizon of Weight Management
Amylin analogues and triple agonists in late-stage trials, and what their endpoints do and do not show.
Dr. Laila Varma
Contributing Clinician
Aug 3, 2026 • 18 min
What the data says
20–24%
Mean total body-weight reduction reported at 72 weeks in the strongest published multi-agonist trials.
Source: Phase III trial publications
The first generation of incretin therapies established that pharmacological appetite suppression can produce weight loss previously seen only after bariatric surgery. The current wave — dual and triple agonists layering GIP and glucagon activity onto GLP-1 — pushes mean reductions higher while raising new questions about composition of the loss.
Read these trials for three things: what fraction of the loss was lean mass, what happened in the withdrawal arms, and how discontinuation rates from gastrointestinal side effects were handled in the analysis.
None of this is medical advice, and the appropriate use of these drugs is a decision for a clinician with your history in front of them. What the evidence does settle is that obesity responds to biological intervention, which makes the moralised framing of the last three decades hard to defend.
Editorial note: this article summarises published research for general information. It is not medical advice. Discuss any intervention with a qualified clinician.
